NOT-NS-23-105: Notice of Change to Award Budget for RFA-NS-21-029, "HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)

Notice of Change to Award Budget for RFA-NS-21-029, "HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)”

Notice Number:

NOT-NS-23-105

Key Dates

Release Date:

August 9, 2023

Related Announcements

June 8, 2021 - HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed). See NOFO RFA-NS-21-029.

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform applicants of a change to the Award Budget for RFA-NS-21-029 "HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)”. The Award Budget changes to the Notice of Funding Opportunity (NOFO) are shown below. This notice is effective for the October 10, 2023 due date.

Currently Reads:

Part 2. Full Text of Announcement

Section II. Award Information

Award Budget

The direct costs for each year of the project may not exceed $500,000, including consortium costs.

Modified to Read:

Part 2. Full Text of Announcement

Section II, Award Information

Award Budget

Application budgets are limited to direct costs of $500,000 per year.

All others aspects of this NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Julia L. Bachman, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Email: julia.bachman@nih.gov